 |
| Dr Mahima Kapoor is the first author on a study which shows higher risk for patients who have suffered clotting events from a particular treatment, intravenous immunoglobulin. |
by Dr Loretta Piccenna, Department of Neuroscience
An important analysis using the UK Biobank published this month by researchers in the Neuromuscular group in the Department of Neuroscience has shown a three-fold higher risk of blood clots, or thromboembolic events (TEEs), in patients with a prior history of these events when they were treated with intravenous immunoglobulin (IVIg) (1).
